B. Riley Analysts Increase Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at B. Riley increased their Q1 2025 EPS estimates for shares of Eton Pharmaceuticals in a research report issued on Wednesday, March 19th. B. Riley analyst M. El-Saadi now anticipates that the company will earn $0.06 per share for the quarter, up from their prior estimate of $0.03. B. Riley currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.00 EPS.

A number of other brokerages also recently issued reports on ETON. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research note on Wednesday.

Eton Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ ETON opened at $14.78 on Thursday. The company has a market cap of $385.03 million, a P/E ratio of -67.18 and a beta of 1.37. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $18.41. The business has a 50-day simple moving average of $15.56 and a two-hundred day simple moving average of $11.47.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The firm had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC increased its position in shares of Eton Pharmaceuticals by 12.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company’s stock worth $14,898,000 after purchasing an additional 119,750 shares during the last quarter. Westside Investment Management Inc. lifted its position in Eton Pharmaceuticals by 5.7% during the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after purchasing an additional 33,275 shares during the last quarter. Mink Brook Asset Management LLC purchased a new position in Eton Pharmaceuticals in the 4th quarter worth approximately $6,071,000. Cannell Capital LLC bought a new position in shares of Eton Pharmaceuticals in the 4th quarter worth $5,079,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Eton Pharmaceuticals by 6.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock valued at $3,688,000 after buying an additional 16,664 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.